Seladelpar is an investigational drug.
There have been 11 clinical trials for Seladelpar.
The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2018.
The most common disease conditions in clinical trials are Cholangitis, Liver Cirrhosis, Biliary, and Liver Diseases. The leading clinical trial sponsors are CymaBay Therapeutics, Inc. and [disabled in preview].
There are twenty-one US patents protecting this investigational drug and three hundred and one international patents.